This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Collegium Pharmaceutical (COLL) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Collegium Pharmaceutical (COLL) shares rose 6% in the last trading session, amid huge volumes.
Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session
by Zacks Equity Research
Aldeyra Therapeutics (ALDX) saw a big move last session, as its shares jumped more than 34% on the day, amid huge volumes.
3 Reasons Momentum Stock Investors Will Love Corbus Pharmaceuticals Holdings (CRBP)
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
Advanced Accelerator Applications (AAAP) in Focus: Stock Moves 7.5% Higher
by Zacks Equity Research
Advanced Accelerator Applications S.A. (AAAP) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Surging Earnings Estimates Signal Good News for Corbus Pharmaceuticals (CRBP)
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
Play the Marijuana Rush as First Marijuana-Focused ETF Launches
by Arpita Dutt
The medical marijuana industry has been gaining a lot of importance and attracting interest from investors over the last few quarters with companies like GW Pharma (GWPH) making headlines.
Corbus Concludes Phase II study of Cystic Fibrosis Candidate
by Zacks Equity Research
Corbus Pharmaceuticals Holdings, Inc. (CRBP), recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF).